Prospective phase II trial of combination hepatic artery infusion and systemic chemotherapy for unresectable colorectal liver metastases: Long term results and curative potential
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Background/Objectives: Combination hepatic artery infusion (HAI) and systemic (SYS) chemotherapy for unresectable CRLM results in high tumor‐response rates. This study represents an update of long‐term survival and conversion to resectability in patients with unresectable CRLM treated with HAI and SYS chemotherapy in a phase II study. Method: The primary endpoint was complete resection. Multivariate and landmark analysis assessed the effect of complete resection on progression‐free (PFS) and overall survival (OS). Results: From 2007 to 2012, 64 patients with median of 13 tumors were enrolled; 67% had prior chemotherapy. 33 patients (52%) were converted to resection. Median follow‐up among survivors was 81 months. Median PFS and OS were 13 and 38 months, respectively, with 5‐year‐OS of 36%. Chemotherapy‐naïve patients had 5‐year‐OS of 51%. Conversion to resection was the only independent factor prognostic of improved PFS and OS. Nine of 64 patients (14%) are NED (five since initial resection, three after resection of recurrent disease, one from chemotherapy alone) at median follow‐up of 86 months from treatment initiation, and 72 months from last operative intervention. Conclusion: Combination HAI and SYS is an effective therapy for high‐volume unresectable CRLM, resulting in a high rate of resection, long‐term survival, and the potential for cure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877
Global patterns of cancer incidence and mortality rates and trends
Jemal, A., Center, M. M., DeSantis, C., & Ward, E. M. (2010) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-10-0437 · Cited by 2,778
Van Cutsem, E., Köhne, C.-H., Láng, I., Folprecht, G., Nowacki, M. P., Cascinu, S., Shchepotin, I., Maurel, J., Cunningham, D., Tejpar, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.5091 · Cited by 1,882
Hecht, J. R., Mitchell, E., Chidiac, T., Scroggin, C., Hagenstad, C., Spigel, D., Marshall, J., Cohn, A., McCollum, D., Stella, P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8135 · Cited by 850
Nash, G. M., Gimbel, M., Shia, J., Nathanson, D. R., Ndubuisi, M. I., Zeng, Z.-S., Kemeny, N., & Paty, P. B. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0605-3 · Cited by 172 · cited 1×
“We did not find a significant association in our study between KRAS mutational status and conversion to resection or survival outcomes, which is potentially due to the relatively small size of the study population compared to prior studies and as this study was not powered to perform this subgroup analysis.(50,51) How…”
ResultSelf-citationBorner, M., Koeberle, D., Von Moos, R., Saletti, P., Rauch, D., Hess, V., Trojan, A., Helbling, D., Pestalozzi, B., Caspar, C., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn058 · Cited by 124
Cited by
Vogel, J. D., Felder, S. I., Bhama, A. R., Hawkins, A. T., Langenfeld, S. J., Shaffer, V. O., Thorsen, A. J., Weiser, M. R., Chang, G. J., Lightner, A. L., et al. (2022) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0000000000002323 · Cited by 401
Current Surgical Management Strategies for Colorectal Cancer Liver Metastases
Ivey, G. D., Johnston, F. M., Azad, N. S., Christenson, E. S., Lafaro, K. J., & Shubert, C. R. (2022) · Cancers · doi:10.3390/cancers14041063 · Cited by 70
“Rates of conversion to resectability following this combination have been reported as high as 52% [92].”
BackgroundCurrent status of surgical treatment of colorectal liver metastases
Xu, F., Tang, B., Jin, T.-Q., & Dai, C.-L. (2018) · World Journal of Clinical Cases · doi:10.12998/wjcc.v6.i14.716 · Cited by 45
Oligometastatic Colorectal Cancer: A Review of Definitions and Patient Selection for Local Therapies
Miller, E. D., Hitchcock, K. E., & Romesser, P. B. (2023) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-022-00900-5 · Cited by 31
“Pak et al. reported on a single-institution phase II trial of 64 patients with unresectable colorectal liver metastases treated with combination HAIP and modern systemic chemotherapy [45].”
Metadata
- Authors
- Pak, L. M., Kemeny, N. E., Capanu, M., Chou, J. F., Boucher, T., Cercek, A., Balachandran, V. P., Kingham, T. P., Allen, P. J., DeMatteo, R. P., Jarnagin, W. R., & D'Angelica, M. I.
- Venue
- Journal of Surgical Oncology
- Publisher
- Wiley
- Published
- 2017-11-22
- Volume
- 117
- Issue
- 4
- Pages
- 634-643
- ISSN
- 0022-4790 (ISSN-L)
- 1096-9098
- OpenAlex
- W2768830411
- Cited by
- 119
- References
- 6
- FWCI
- 2.80
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prospective phase II trial of combination hepatic artery infusion and systemic chemotherapy for unresectable colorectal liver metastases: Long term results and curative potential. https://app.cochat.ai/papers/10.1002/jso.24898
- The paper
- Pak, L. M., Kemeny, N. E., Capanu, M., Chou, J. F., Boucher, T., Cercek, A., Balachandran, V. P., Kingham, T. P., Allen, P. J., DeMatteo, R. P., Jarnagin, W. R., & D'Angelica, M. I. (2018). Prospective phase II trial of combination hepatic artery infusion and systemic chemotherapy for unresectable colorectal liver metastases: Long term results and curative potential. Journal of Surgical Oncology. https://doi.org/10.1002/jso.24898
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.